Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (151-160 of 298) with videos related to

Pageof 30
Sort By:
Journal of the American Academy of Dermatology|June 24, 2008
Rethinking eligibility creepMaryanne Kazanis, Craig Leonardi, Ken Gordon, et al.
Journal of Drugs in Dermatology : JDD|February 18, 2004
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisAlan Menter, Mark Kosinski, Brian W Bresnahan, et al.
Plastic and Reconstructive Surgery|September 16, 2003
Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar linesJean D Carruthers, Nicolas J Lowe, M Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2020
Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in PsoriasisLawrence Green, Jeffrey M. Weinberg, Alan Menter, et al.
Skinmed|May 23, 2017
Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled StudiesAlan Menter, Linda Stein Gold, John Koo, et al.
Dermatology and Therapy|September 1, 2016
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 StudiesAlan Menter, Jennifer C Cather, Michael Jarratt, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Long-term management of plaque psoriasis with continuous efalizumab therapyAlan Menter, Craig L Leonardi, Wolfram Sterry, et al.
Journal of Drugs in Dermatology : JDD|February 3, 2009
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasisAlan Menter, William Abramovits, Luz E Colón, et al.
Journal of the American Academy of Dermatology|July 8, 2010
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasisAlan Menter, Kenneth B Gordon, Craig L Leonardi, et al.
Journal of Drugs in Dermatology : JDD|March 6, 2014
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regionsAlan Menter, Kim A Papp, Huaming Tan, et al.
Pageof 30

Showing results (151-160 of 298) with videos related to

Sort By:
Pageof 30
Journal of the American Academy of Dermatology|June 24, 2008
Rethinking eligibility creepMaryanne Kazanis, Craig Leonardi, Ken Gordon, et al.
Journal of Drugs in Dermatology : JDD|February 18, 2004
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisAlan Menter, Mark Kosinski, Brian W Bresnahan, et al.
Plastic and Reconstructive Surgery|September 16, 2003
Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar linesJean D Carruthers, Nicolas J Lowe, M Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|March 5, 2020
Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in PsoriasisLawrence Green, Jeffrey M. Weinberg, Alan Menter, et al.
Skinmed|May 23, 2017
Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled StudiesAlan Menter, Linda Stein Gold, John Koo, et al.
Dermatology and Therapy|September 1, 2016
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 StudiesAlan Menter, Jennifer C Cather, Michael Jarratt, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Long-term management of plaque psoriasis with continuous efalizumab therapyAlan Menter, Craig L Leonardi, Wolfram Sterry, et al.
Journal of Drugs in Dermatology : JDD|February 3, 2009
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasisAlan Menter, William Abramovits, Luz E Colón, et al.
Journal of the American Academy of Dermatology|July 8, 2010
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasisAlan Menter, Kenneth B Gordon, Craig L Leonardi, et al.
Journal of Drugs in Dermatology : JDD|March 6, 2014
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regionsAlan Menter, Kim A Papp, Huaming Tan, et al.
Pageof 30